A medicine group, then a product
Weight medicines need their own names
In a few words
A hormone is a message sent within the body. GLP-1 is one that affects blood sugar and appetite.
The group name does not pick a treatment
Some drugs copy the hormone’s signal.
Semaglutide (Ozempic, Wegovy) had approved US products as of September 2026. So did tirzepatide (Mounjaro, Zepbound).
Ask which use is relevant to your health. Then ask whether it addresses your aim for weight, body fat or muscle. Keep the answer separate from a claim about appearance.
A past shortage does not settle a current offer
FDA means Food and Drug Administration. This agency reviews drugs in the US.
The injections of both drugs were off the national shortage list in September 2026.
An empty shelf nearby is not the national shortage record.
While those injections were on FDA’s shortage list, the shortage rules allowed pharmacies to prepare copies of the listed drugs. Those copies still had to meet the other compounding rules.
Ask for the present reason for a compounded offer, rather than relying on an old account of supply problems.
Return to the compounding distinction